John Caldwell

Institute of Cancer Research — United Kingdom

Physics and Astronomy · Physical Sciences

56h-index12.6kcitations798works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Astro and Planetary Science(154), Musicology and Musical Analysis(92), Planetary Science and Exploration(91), Pharmacogenetics and Drug Metabolism(43), Diverse Musicological Studies(43)

Publications798 total

Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening
Scientific Reports·2025Open Access
Discovery of first-in-class inhibitors of the TRF1-TIN2 protein-protein interaction by fragment screening
2025Open Access
Evaluating the impact of <i>CRBN</i> mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
Blood·2025· 6 citedOpen Access
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iScience·2024Open Access
THE MUSICAL LANGUAGE OF INDIAN FILM SONG OF THE 1940s
2023Open Access
Front Cover: A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity (ChemBioChem 23/2023)
ChemBioChem·2023Open Access
Determination of Ligand-Binding Affinity (<i>K</i><sub>d</sub>) Using Transverse Relaxation Rate (<i>R</i><sub>2</sub>) in the Ligand-Observed <sup>1</sup>H NMR Experiment and Applications to Fragment-Based Drug Discovery
Journal of Medicinal Chemistry·2023· 19 citedOpen Access
A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity**
ChemBioChem·2023· 15 citedOpen Access
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iScience·2023· 13 citedOpen Access
Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Supplementary Figure Legends and Supplementary Table 1 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Supplementary Figure Legends and Supplementary Table 1 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Data from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Data from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2023Open Access
Data from Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis
2023Open Access
Supplementary Figure S4 from Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis
2023Open Access
Supplementary Figure S3 from Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis
2023Open Access
Data from CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
2023Open Access
Movie S1 Vehicle from Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis
2023Open Access
page 1 of 40Next →

Frequent Co-authors

Robert L. Smith(7), Ian Collins(7), Andrew J. Hutt(5), Michelle D. Garrett(5), Glenn S. Orton(3), Martin Rowlands(3), Ruth Ruddle(3), Florence I. Raynaud(3), Paul Workman(3), D. L. Judge(3), Chao Wu(3), J. Gerry Kenna(2), Richard Wagener(2), A. J. Hutt(2), Paul D. Eve(2), Wynne Aherne(2), A. T. Tokunaga(2), Thomas G. Davies(2), Tatiana McHardy(2), G. Wynne Aherne(2)